Alesco Advisors’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Alesco Advisors’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-2,228	Closed	-$22K	–	122
2017 Q2	$22K	Hold	2,228	–	–	﹤0.01%	114
2017 Q1	$54K	Hold	2,228	–	–	﹤0.01%	112
2016 Q4	$72K	Hold	2,228	–	–	0.01%	108
2016 Q3	$111K	Hold	2,228	–	–	0.01%	110
2016 Q2	$94K	Hold	2,228	–	–	0.01%	106
2016 Q1	$147K	Hold	2,228	–	–	0.01%	104
2015 Q4	$139K	Hold	2,228	–	–	0.01%	106
2015 Q3	$149K	Hold	2,228	–	–	0.01%	103
2015 Q2	$217K	Hold	2,228	–	–	0.02%	104
2015 Q1	$208K	Hold	2,228	–	–	0.02%	98
2014 Q4	$198K	Hold	2,228	–	–	0.02%	98
2014 Q3	$154K	Hold	2,228	–	–	0.02%	94
2014 Q2	$128K	Sell	2,228 -814	-27%	-$41.3K	0.01%	92
2014 Q1	$121K	Hold	3,042	–	–	0.01%	88
2013 Q4	$128K	Buy	+3,042	New	+$88.2K	0.01%	82

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Alesco Advisors's MACK Position: Q3 2017 in Review

Alesco Advisors sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2017, closing a stake of 2,228 shares — an estimated $22K sold.

Alesco Advisors first reported a position in MACK in Q4 2013 and held it in 15 quarters. The position peaked at $217K in Q2 2015. 73 funds tracked by Wall St. Rank hold MACK as of Q3 2017.

Alesco Advisors reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
Alesco Advisors sold 2,228 Merrimack Pharmaceuticals, Inc. shares in Q3 2017, an estimated $22K.
Alesco Advisors first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2013 and held it in 15 quarters.
Alesco Advisors's Merrimack Pharmaceuticals, Inc. position peaked at $217K in Q2 2015.
73 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2017.

Based on Alesco Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.